Clinical TrialsPromising early clinical results showcasing the potential doubling of progression-free survival and overall survival rates in glioma patients treated with CLD-101 could signal a breakthrough in cancer treatment efficacy.
Funding And CollaborationThe collaboration with City of Hope, boosted by a significant grant, not only aids the development of CLD-101 but also strengthens Calidi's position in the pursuit of innovative cancer treatments.
Research And DevelopmentCalidi Biotherapeutics is advancing the field of cancer therapy with its RTNova program, aiming to provide a novel treatment for challenging solid tumors, including lung cancer and metastatic cancer.